-
Je něco špatně v tomto záznamu ?
Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry
M. Zurkova, E. Kriegova, V. Kolek, V. Lostakova, M. Sterclova, V. Bartos, M. Doubkova, I. Binkova, M. Svoboda, J. Strenkova, M. Janotova, M. Plackova, L. Lacina, V. Rihak, F. Petrik, P. Lisa, R. Bittenglova, R. Tyl, G. Ondrejka, H. Suldova, J....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
BioMedCentral
od 2000-01-04
BioMedCentral Open Access
od 2000
Directory of Open Access Journals
od 2000
Free Medical Journals
od 2000
PubMed Central
od 2000
Europe PubMed Central
od 2000
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2000-01-01
Open Access Digital Library
od 2000-06-01
Open Access Digital Library
od 2000-01-01
Medline Complete (EBSCOhost)
od 2000-01-01
Health & Medicine (ProQuest)
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2000
Springer Nature OA/Free Journals
od 2000-04-01
- MeSH
- antiflogistika nesteroidní farmakologie terapeutické užití MeSH
- idiopatická plicní fibróza diagnóza farmakoterapie epidemiologie MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití trendy MeSH
- následné studie MeSH
- progrese nemoci * MeSH
- pyridony farmakologie terapeutické užití MeSH
- registrace * MeSH
- respirační funkční testy trendy MeSH
- senioři MeSH
- vitální kapacita účinky léků fyziologie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
INTRODUCTION: Pirfenidone, an antifibrotic drug, slows-down the disease progression in idiopathic pulmonary fibrosis (IPF) over 12 months, however limited data on the decline of lung function and overall survival (OS) in real-world cohorts on longer follow-up exists. PATIENTS/METHODS: Of the enrolled Czech IPF patients (n = 841) from an EMPIRE registry, 383 (45.5%) received pirfenidone, 218 (25.9%) no-antifibrotic treatment and 240 (28.5%) were excluded (missing data, nintedanib treatment). The 2- and 5-yrs OS and forced vital capacity (FVC) and diffusing lung capacity for carbon monoxide (DLCO) were investigated at treatment initiation and 6, 12, 18 and 24 months' follow-up. RESULTS: During a 2-yr follow-up, less than a quarter of the patients progressed on pirfenidone as assessed by the decline of ≥10% FVC (17.0%) and ≥ 15% DLCO (14.3%). On pirfenidone, the DLCO (≥10%) declines at 6, 12, 18 and 24 months' and DLCO (≥15%) declines at 6, 18 and 24 months' follow-up were associated with increased mortality. The DLCO decline showed higher predictive value for mortality than FVC decline. In patients with no-antifibrotics, FVC and DLCO declines were not predictive for mortality. Pirfenidone increased 5-yrs OS over no-antifibrotic treatment (55.9% vs 31.5% alive, P = 0.002). CONCLUSION: Our study observed the 2-yrs sustained effect of pirfenidone on the decline of lung function and survival in the real-world patient's IPF cohort. DLCO decline of ≥10% shows a potential as a mortality predictor in IPF patients on pirfenidone, and should be routinely evaluated during follow-up examinations.
Department of Pulmonary Medicine and Allergology Hospital Kromeriz Kromeriz Czech Republic
Department of Pulmonary Medicine and Thoracic Surgery Hospital Na Bulovce Prague Czech Republic
Department of Pulmonary Medicine Hospital Ceske Budejovice Ceske Budejovice Czech Republic
Department of Pulmonary Medicine Hospital Jihlava Jihlava Czech Republic
Department of Pulmonary Medicine Hospital Novy Jicin Novy Jicin Czech Republic
Department of Pulmonary Medicine Hospital Znojmo Znojmo Czech Republic
Department of Pulmonary Medicine Regional Hospital Pardubice Pardubice Czech Republic
Department of Pulmonary Medicine Tomas Bata Regional Hospital Zlin Czech Republic
Department of Pulmonary Medicine University Hospital Plzen Pilsen Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19011958
- 003
- CZ-PrNML
- 005
- 20231124110421.0
- 007
- ta
- 008
- 190405s2019 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12931-019-0977-2 $2 doi
- 035 __
- $a (PubMed)30665416
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Zurkova, Monika $u Department of Pulmonary Diseases and Tuberculosis, Faculty of Medicine and Dentistry, Palacky University in Olomouc, University Hospital Olomouc, Olomouc, Czech Republic.
- 245 10
- $a Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry / $c M. Zurkova, E. Kriegova, V. Kolek, V. Lostakova, M. Sterclova, V. Bartos, M. Doubkova, I. Binkova, M. Svoboda, J. Strenkova, M. Janotova, M. Plackova, L. Lacina, V. Rihak, F. Petrik, P. Lisa, R. Bittenglova, R. Tyl, G. Ondrejka, H. Suldova, J. Lnenicka, J. Psikalova, T. Snizek, J. Homolka, R. Kralova, J. Kervitzer, M. Vasakova, . , . ,
- 520 9_
- $a INTRODUCTION: Pirfenidone, an antifibrotic drug, slows-down the disease progression in idiopathic pulmonary fibrosis (IPF) over 12 months, however limited data on the decline of lung function and overall survival (OS) in real-world cohorts on longer follow-up exists. PATIENTS/METHODS: Of the enrolled Czech IPF patients (n = 841) from an EMPIRE registry, 383 (45.5%) received pirfenidone, 218 (25.9%) no-antifibrotic treatment and 240 (28.5%) were excluded (missing data, nintedanib treatment). The 2- and 5-yrs OS and forced vital capacity (FVC) and diffusing lung capacity for carbon monoxide (DLCO) were investigated at treatment initiation and 6, 12, 18 and 24 months' follow-up. RESULTS: During a 2-yr follow-up, less than a quarter of the patients progressed on pirfenidone as assessed by the decline of ≥10% FVC (17.0%) and ≥ 15% DLCO (14.3%). On pirfenidone, the DLCO (≥10%) declines at 6, 12, 18 and 24 months' and DLCO (≥15%) declines at 6, 18 and 24 months' follow-up were associated with increased mortality. The DLCO decline showed higher predictive value for mortality than FVC decline. In patients with no-antifibrotics, FVC and DLCO declines were not predictive for mortality. Pirfenidone increased 5-yrs OS over no-antifibrotic treatment (55.9% vs 31.5% alive, P = 0.002). CONCLUSION: Our study observed the 2-yrs sustained effect of pirfenidone on the decline of lung function and survival in the real-world patient's IPF cohort. DLCO decline of ≥10% shows a potential as a mortality predictor in IPF patients on pirfenidone, and should be routinely evaluated during follow-up examinations.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antiflogistika nesteroidní $x farmakologie $x terapeutické užití $7 D000894
- 650 _2
- $a kohortové studie $7 D015331
- 650 12
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a idiopatická plicní fibróza $x diagnóza $x farmakoterapie $x epidemiologie $7 D054990
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a pyridony $x farmakologie $x terapeutické užití $7 D011728
- 650 12
- $a registrace $7 D012042
- 650 _2
- $a respirační funkční testy $x trendy $7 D012129
- 650 _2
- $a míra přežití $x trendy $7 D015996
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a vitální kapacita $x účinky léků $x fyziologie $7 D014797
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kriegova, Eva $u Department of Immunology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacky University in Olomouc, Hnevotinska 3, 775 15, Olomouc, Czech Republic. eva.kriegova@email.cz.
- 700 1_
- $a Kolek, Vitezslav $u Department of Pulmonary Diseases and Tuberculosis, Faculty of Medicine and Dentistry, Palacky University in Olomouc, University Hospital Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Lostakova, Vladimira $u Department of Pulmonary Diseases and Tuberculosis, Faculty of Medicine and Dentistry, Palacky University in Olomouc, University Hospital Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Sterclova, Martina $u Department of Respiratory Medicine, 1st Faculty of Medicine Charles University in Prague, Thomayer Hospital, Prague, Czech Republic.
- 700 1_
- $a Bartos, Vladimir $u Department of Pulmonary Medicine, Faculty of Medicine in Hradec Kralove at Charles University in Prague, University Hospital Hradec Kralove, Prague, Czech Republic.
- 700 1_
- $a Doubkova, Martina $u Department of Pulmonary Diseases and Tuberculosis, Faculty of Medicine at Masaryk University, University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Binkova, Ilona $u Department of Pulmonary Diseases and Tuberculosis, Faculty of Medicine at Masaryk University, University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Svoboda, Michal $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Strenková, Jana $7 xx0235129 $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Janotova, Marketa $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Plackova, Martina $u Department of Pulmonary Diseases and Tuberculosis, Faculty of Medicine at University of Ostrava, University Hospital Ostrava, Ostrava, Czech Republic.
- 700 1_
- $a Lacina, Ladislav $u Department of Pulmonary Medicine and Thoracic Surgery, Hospital Na Bulovce, Prague, Czech Republic.
- 700 1_
- $a Rihak, Vladimir $u Department of Pulmonary Medicine, Tomas Bata Regional Hospital, Zlin, Czech Republic.
- 700 1_
- $a Petrik, Frantisek $u Department of Pulmonary Medicine, 2nd Faculty of Medicine at Charles University in Prague, University Hospital in Motol, Prague, Czech Republic.
- 700 1_
- $a Lisá, Pavlína $u Department of Pulmonary Medicine, 2nd Faculty of Medicine at Charles University in Prague, University Hospital in Motol, Prague, Czech Republic. $7 xx0310633
- 700 1_
- $a Bittenglová, Radka, $d 1966- $7 xx0110170 $u Department of Pulmonary Medicine, University Hospital Plzen, Pilsen, Czech Republic.
- 700 1_
- $a Tyl, Richard $u Department of Pulmonary Diseases and Tuberculosis, Faculty of Medicine at University of Ostrava, University Hospital Ostrava, Ostrava, Czech Republic.
- 700 1_
- $a Ondrejka, Gustav $u Department of Pulmonary Medicine, Hospital Novy Jicin, Novy Jicin, Czech Republic.
- 700 1_
- $a Suldova, Hana $u Department of Pulmonary Medicine, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic.
- 700 1_
- $a Lnenicka, Jaroslav $u Department of Pulmonary Diseases and Tuberculosis, Regional Medical Association, JSC - Masaryk Hospital in Usti nad Labem, Usti nad Labem, Czech Republic.
- 700 1_
- $a Psikalova, Jana $u Department of Pulmonary Medicine and Allergology, Hospital Kromeriz, Kromeriz, Czech Republic.
- 700 1_
- $a Snizek, Tomas $u Department of Pulmonary Medicine, Hospital Jihlava, Jihlava, Czech Republic.
- 700 1_
- $a Homolka, Jiri $u Department of Respiratory Medicine, 1st Faculty of Medicine Charles University in Prague, Thomayer Hospital, Prague, Czech Republic.
- 700 1_
- $a Kralova, Renata $u Department of Pulmonary Medicine, Regional Hospital Pardubice, Pardubice, Czech Republic.
- 700 1_
- $a Kervitzer, Jan $7 xx0245394 $u Department of Pulmonary Medicine, Hospital Znojmo, Znojmo, Czech Republic.
- 700 1_
- $a Vasakova, Martina $u Department of Respiratory Medicine, 1st Faculty of Medicine Charles University in Prague, Thomayer Hospital, Prague, Czech Republic.
- 700 1_
- $a ,
- 700 1_
- $a ,
- 773 0_
- $w MED00006600 $t Respiratory research $x 1465-993X $g Roč. 20, č. 1 (2019), s. 16
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30665416 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20231124110414 $b ABA008
- 999 __
- $a ok $b bmc $g 1391268 $s 1050263
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 20 $c 1 $d 16 $e 20190121 $i 1465-993X $m Respiratory research $n Respir Res $x MED00006600
- LZP __
- $a Pubmed-20190405
